Cerenome CEO Hedrick acquires shares as grants vest

Each restricted stock unit represents a contingent right to receive one share of Cerenome common stock.

Rhea-AI Filing Summary

Cerenome, Inc. CEO and director Marc H. Hedrick reported vesting of three restricted stock unit grants on October 1, 2026, and acquired 6,387, 8,066 and 1,986 shares of common stock, respectively. The grants vest in 12 substantially equal quarterly installments, with schedules beginning on October 1, 2025, April 1, 2026 and July 1, 2026, respectively.

Insider Trade Summary

16,439 shares exercised/converted

Exercise 6 txns

Insider HEDRICK MARC H

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F2	6,387	$0.00	$0.00
Exercise	Restricted Stock Units F3	8,066	$0.00	$0.00
Exercise	Restricted Stock Units F4	1,986	$0.00	$0.00
Exercise	Common Stock F2, F1	6,387	$0.00	$0.00
Exercise	Common Stock F3, F1	8,066	$0.00	$0.00
Exercise	Common Stock F4, F1	1,986	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 137,159 contracts (Direct); Common Stock — 60,922 shares (Direct)

Footnotes (4)

1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.
2. F2. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025.
3. F3. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on April 1, 2026.
4. F4. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on July 1, 2026.

Key Figures

Common shares acquired from first RSU grant: 6,387 shares Common shares acquired from second RSU grant: 8,066 shares Common shares acquired from third RSU grant: 1,986 shares +1 more

4 metrics

Common shares acquired from first RSU grant 6,387 shares Grant vesting reported October 1, 2026; installments began October 1, 2025

Common shares acquired from second RSU grant 8,066 shares Grant vesting reported October 1, 2026; installments began April 1, 2026

Common shares acquired from third RSU grant 1,986 shares Grant vesting reported October 1, 2026; installments began July 1, 2026

Vesting installments 12 substantially equal quarterly installments Each of the three RSU grants

Key Terms

vesting, contingent right, substantially equal quarterly installments

3 terms

vesting financial

"Represents the vesting of an RSU grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

contingent right financial

"contingent right to receive one share of the issuer's Common Stock"

substantially equal quarterly installments financial

"occurs in twelve substantially equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did CNSY CEO Marc H. Hedrick acquire from RSUs?

On October 1, 2026, Marc H. Hedrick acquired 6,387, 8,066 and 1,986 shares of common stock as three RSU grants vested. The grants followed 12 substantially equal quarterly installments, beginning October 1, 2025, April 1, 2026 and July 1, 2026, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 08:00 AM Accepted by SEC EDGAR 10/01/2026 - 08:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEDRICK MARC H

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CERENOME, INC. [ CNSY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2026		M		6,387(2)	A	$0(1)	50,870	D
Common Stock	10/01/2026		M		8,066(3)	A	$0(1)	58,936	D
Common Stock	10/01/2026		M		1,986(4)	A	$0(1)	60,922	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	10/01/2026		M			6,387	(2)	(2)	Common Stock	6,387	$0	147,211	D
Restricted Stock Units	$0	10/01/2026		M			8,066	(3)	(3)	Common Stock	8,066	$0	139,145	D
Restricted Stock Units	$0	10/01/2026		M			1,986	(4)	(4)	Common Stock	1,986	$0	137,159	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.

2. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025.

3. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on April 1, 2026.

4. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on July 1, 2026.

	Andrew Sims, as attorney-in-fact	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)